Last reviewed · How we verify
NCT03434639: GutPerm
Fluorescence Spectroscopy for Gut Permeability Assessment
trial testing Spectroscopic gut permeability test in Development and Validation of Gut Permeability Sensor in 50 participants. Status unknown.
30 September 2021
Quick facts
| Lead sponsor | Imperial College London |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 50 |
| Start date | 29 March 2019 |
| Primary completion | 30 September 2021 |
| Estimated completion | 30 September 2021 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- Spectroscopic gut permeability test
Conditions studied
- Development and Validation of Gut Permeability Sensor — all drugs for Development and Validation of Gut Permeability Sensor →
- Permeability; Increased — all drugs for Permeability; Increased →
- Celiac Disease — all drugs for Celiac Disease →
- Inflammatory Bowel Diseases — all drugs for Inflammatory Bowel Diseases →
Sponsor
Imperial College London
Who can join
18 and older, any sex, with Development and Validation of Gut Permeability Sensor or Permeability; Increased. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This research aims to develop portable devices - known as fluorescence spectrometers - to monitor the leakage of fluorescent dyes out of the gut into the blood stream. These devices will measure the leakiness (permeability) of the gut in a non-invasive manner and will provide an early warning that patients are at risk of infections caused by the unwanted flow of bacteria from the intestine to the rest of the body.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Non-invasive fluorescence sensing reveals changes in intestinal barrier function and gastric emptying rate in a first-in-human study of Crohn's disease.
Gan J, Chen Q, Monfort Sanchez E, Mandal N, et al · · 2025 · PMID 40821739 · DOI 10.1177/17562848251361634
Verify or expand the search:
- PubMed search for NCT03434639
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Imperial College London trials
Trials by the same sponsor.
- NCT06035861 — Endothelial Cell Activation and Total Pulmonary Resistance in PAH · NA · not yet recruiting
- NCT07397455 — Development of a Controlled Human Infection Model for Assessment of SARS-CoV-2 Omicron Subvariants · Phase 1 · not yet recruiting
- NCT07422532 — A Multi-centre Trial to Assess the Efficacy and Safety of the Omnipod 5 System in People With Type 2 Diabetes Undergoing · NA · not yet recruiting
- NCT07389031 — Maralixibat for Intrahepatic Cholestasis of Pregnancy · Phase 2 · not yet recruiting
- NCT07358897 — Gender Affirming Hormone Therapy and Immune Function in Trans Individuals - The GIFT Study · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03434639 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Imperial College London
- Last refreshed: 12 February 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03434639.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing